OligoMedicines

Located in Milford, Massachusetts, Avecia Biotechnology Inc. is a recognized leader in therapeutic nucleic acid manufacturing and development services. Avecia provides services for DNA and RNA based therapeutics to customers from pre-clinical through commercial launch. In addition to cGMP (current Good Manufacturing Practices) manufacturing, Avecia's services include the development of analytical methods, process validation, stability studies, quality control, and regulatory support.

Effective 2nd February 2011, Japan's leading diversified materials manufacturer, Nitto Denko Corporation, has acquired Avecia Biotechnology, Inc. through Nitto Americas, Inc., a wholly owned subsidiary in Teaneck, New Jersey. Nitto Denko aims to strengthen its business base in the domain of nucleic acid drugs with this acquisition, in light of the industry's great growth potential. Click here to read the press release.

Biologics

Effective 1st Feb 2010, MSD (operating in the US and Canada as Merck & Co,. Inc.) acquired Avecia Biologics Limited and all its assets. For further information on this business go to www.biomanufacturingnetwork.com